BACKGROUND: Skin injuries and the consequent loss of tissue integrity triggers a sequence of cellular and biochemical events that lead to a healed wound. Any failure during this rather sophisticated process may result in pathological scarring. METHODS: To evaluate the efficacy of topical verapamil as a modulator of the healing process, a group of five observers (plastic surgeon, dermatologist, physiotherapist, biologist, and layman) analyzed pictures of 120 patients 3 months after abdominoplasty (60 patients) and mammoplasty (60 patients). Half of each group of patients used the topical verapamil scar modulator. Pictures were rated using the Stony Brook Scale. RESULTS: According to the classification established by us, the scars in patients who used topical verapamil scar modulator showed better results than those who did not (p < 0.05). Patients treated with verapamil presented good-quality scarring (80 % of mammoplasty scars and 75.2 % abdominoplasty scars), while patients who did not use healing modulators showed 48 and 51.2 % satisfaction for mammoplasty and abdominoplasty scars, respectively. No adverse reactions were observed or reported after the use of topical verapamil. CONCLUSIONS: This is the first clinical trial that reports the use of topical verapamil as a modulator in the healing process in the postoperative period. Based on clinical results and on the high level of reliability and statistical significance, we concluded that verapamil at a concentration of 50 µM is an excellent choice as a scar modulator; its use avoids the development of keloids and hypertrophic scars after plastic surgery.
BACKGROUND:Skin injuries and the consequent loss of tissue integrity triggers a sequence of cellular and biochemical events that lead to a healed wound. Any failure during this rather sophisticated process may result in pathological scarring. METHODS: To evaluate the efficacy of topical verapamil as a modulator of the healing process, a group of five observers (plastic surgeon, dermatologist, physiotherapist, biologist, and layman) analyzed pictures of 120 patients 3 months after abdominoplasty (60 patients) and mammoplasty (60 patients). Half of each group of patients used the topical verapamil scar modulator. Pictures were rated using the Stony Brook Scale. RESULTS: According to the classification established by us, the scars in patients who used topical verapamil scar modulator showed better results than those who did not (p < 0.05). Patients treated with verapamil presented good-quality scarring (80 % of mammoplasty scars and 75.2 % abdominoplasty scars), while patients who did not use healing modulators showed 48 and 51.2 % satisfaction for mammoplasty and abdominoplasty scars, respectively. No adverse reactions were observed or reported after the use of topical verapamil. CONCLUSIONS: This is the first clinical trial that reports the use of topical verapamil as a modulator in the healing process in the postoperative period. Based on clinical results and on the high level of reliability and statistical significance, we concluded that verapamil at a concentration of 50 µM is an excellent choice as a scar modulator; its use avoids the development of keloids and hypertrophic scars after plastic surgery.
Authors: Augusto Cézar Lacerda Brasileiro; Dinaldo Cavalcanti de Oliveira; Pollianne Barbosa da Silva; João Kairo Soares de Lima Rocha Journal: J Vasc Bras Date: 2020-07-06